1.Hanna N，Lilenbaum R，Ansari R，et al. Phase Ⅱ trial of cetuximab in patients with previously treated non-smallcell lung cancer. J Clin Oncol，2006，24（33）：5253-5258.

2.Borghaei H，Langer CJ，Millenson M，et al. Phase Ⅱ study of paclitaxel，carboplatin，and cetuximab as first line treatment，for patients with advanced non-small cell lung cancer（NSCLC）：results of OPN-017.J Thorac Oncol，2008，3（11）：1286-1292.

3.Belani CP，Schreeder MT，Steis RG，et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer：a multicenter phase 2 study. Cancer，2008，113（9）：2512-2517.

4.Butts CA，Bodkin D，Middleman EL，et al. Randomized phase Ⅱ study of gemcitabine plus cisplatin or carboplatin［corrected］，with or without cetuximab，as first-line therapy for patients with advanced or metastatic non smallcell lung cancer. J Clin Oncol，2007，25（36）：5777-5784.

5.Rosell R，Robinet G，Szczesna A，et al. Randomized phase Ⅱ study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.Ann Oncol，2008，19（2）：362-369.

6.Robert F，Blumenschein G，Herbst RS，et al. Phase Ⅰ/Ⅱa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol，2005，23（36）：9089-9096.

7.Thienelt CD，Bunn PA Jr，Hanna N，et al. Multicenter phase Ⅰ/Ⅱ study of cetuximab with paclitaxel and carboplatin in untreated patients with stage Ⅳ non-small-cell lung cancer. J Clin Oncol，2005，23（34）：8786-8793.

8.Pirker R，Pereira JR，Szczesna A，et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer（FLEX）：an open-label randomised phase Ⅲ trial. Lancet，2009，73（9674）：1525-1531.

9.Thatcher N. Advanced NSCLC：Platinum based CT + Erbitux Key Phase Ⅱ/Ⅲ Trials -First-line. WCLC 2009，Abstract No. A3.7.

10.Ramalingam S，Forster J，Naret C，et al. Dual inhibition of the epidermal growth factor receptor with cetuximab，an IgG1 monoclonal antibody，and gefitinib，a tyrosine kinase inhibitor，in patients with refractory non-small cell lung cancer（NSCLC）：a phase Ⅰ study. J Thorac Oncol，2008，3（3）：258-264.

11.Jensen AD，Münter MW，Bischoff H，et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab：the NEAR protocol（NCT00115518）. BMC Cancer，2006 May 8；6：122.

12.Hughes S，Liong J，Miah A，et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage Ⅲ non-small cell lung cancer（NSCLC）：SCRATCH study. J Thorac Oncol，2008，3（6）：648-651.

13.Hirsch FR，Herbst RS，Olsen C，et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol，2008，26（20）：3351-3357.

14.Karapetis CS，Khambata-Ford S，Jonker DJ，et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med. 2008，359（17）：1757-1765.

15.Pirker R，Rodrigues-Pereira J，Szczesna A，et al. Prognostic factors in advanced NSCLC：Experience from the FLEX trial. J Clin Oncol，2009，15（Suppl），472（abstr 8083）.

16.Akashi Y，Okamoto I，Iwasa T，et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab，a humanised monoclonal antibody to the epidermal growth factor receptor，in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. British J Cancer，2008，98（4）：749-755.

17.Crawford J，Sandler AB，Hammond LA，et al. ABXEGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer（NSCLC） ［Meeting Abstracts］. J Clin Oncol，2004，22：7083.

18.Blumenschein G，Jr.Sandler A，O’Rourke T，et al. Safety and pharmacokinetics（PK） of AMG 706，panitumumab，and carboplatin/paclitaxel（CP） for the treatment of patients（pts） with advanced non-small cell lung cancer（NSCLC） ［Meeting Abstracts］. J Clin Oncol，2006，24：7119.

19.Crawford J，Burris Iii HA，Stein M，et al. Safety and pharmacokinetics（PK） of AMG 706，panitumumab，and gemcitabine/cisplatin（GC）for the treatment of advanced solid malignancies ［Meeting Abstracts］. ASCO，2006，24：13005.

20.Crombet T，Osorio M，Cruz T，et al. Use of the humanized anti epidermal growth factor receptor monoclonal antibody h r3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Onco1，2004，22（9）：1646-1654.

21.Crombet Ramos T，Rak J，Perez R，et al.Antiproliferative，antiangiogenic and proapoptotic activity of hR3：A humanized anti EGFR antibody.Int J Cancer，2002，101（6）：567-575.

22.Crombet T，TorresL，Neninger E，et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor，monoclonal antibody h-R3，in patients with advanced epithelial-derived cancer. J Immunother，2003，26（2）：139-148.

23.Cromber T，Figueredo J，et al. Treatment of high grade astrocytic tumors with the humanized anti EGFR antibody hR3 and radiotherapy. J Clin Oncol，2005，23（16S）：2554.

24.Bode U，Buchen S. Results of a phaseⅡ trial of h R3 monoclonal antibody（nimotuzumab） in the treatment of resistant or relapsed high grade gliomas in children and adolescents. J Clin Oncol，2006，24（18S）：1522.

25.Gerber DE，Choy H. Cetuximab in combination therapy：from bench to clinic. Cancer Metastasis Rev，2010，29（1）：171-180.

26.陈明，刘凤华.西妥昔单抗联合塞来昔布对肺腺癌细胞KDR和AQP1表达的影响.中国老年学杂志，2014，34（10）：2803-2806.

27.仲琴，朱卫国，李涛，等.表皮生长因子受体单克隆抗体对胶质瘤U87细胞放疗敏感性的影响.中华实验外科杂志ISTIC PKU，2011，28（10）：1734-1736.

28.李伟，林志，齐卫红，等.全人源和人鼠嵌合抗EGFR单克隆抗体临床前安全性对比.中国毒理学会第六届全国毒理学大会论文摘要.2013.

29.Zhang L，Zhao G，Hou Y，et al. The experimental study on the treatment of cytokine-induced killer cells combined with EGFR monoclonal antibody against gastric cancer. Cancer biother Radioharm，2014，29（3）：99-107.

30.孙广伟，李华章，王本锋，等.EGFR单克隆抗体西妥昔单抗联合化疗治疗胃癌的临床应用价值.西部医学，2013，25（4）：528-530.

31.刘静，王斌斌，刘斐叶，等.人鼻咽癌细胞株中表皮生长因子受体蛋白表达与西妥昔单抗抑制率的相关性研究.中国临床医学，2012，19（6）：582-584.

32.张敏，王雪峰.西妥昔单抗与树突状细胞对头颈部鳞状细胞癌杀伤作用的研究.临床耳鼻咽喉头颈外科杂志，2014，28（15）：1133-1136.

33.李馨艳，费小非，杨梅.西妥昔单抗引起味觉、嗅觉丧失1例.中国新药杂志，2013，22（7）；857-858.

34.江灏，陈英，何菊英.西妥昔单抗致大疱性药疹及口腔黏膜损害.药物不良反应杂志ISTIC，2013，15（3）：164-165.

35.雷飞.尼妥珠单抗联合平阳霉素对人舌鳞癌Tca8113细胞体外杀伤作用的研究.兰州大学，2013.

36.Petrelli F，Borgonovo K，Cabiddu M，et al. Risk of anti-EGFR monoclonal antibody-related hypomagnesemia：systematic review and pooled analysis of randomized studies.Expert Opin Drug Saf，2012，11 Suppl 1：S9-S19.

37.Strumberg D，Schultheis B，Scheulen ME，et al. Phase Ⅱ study of nimotuzumab，a humanized monoclonal antiepidermal growth factor receptor（EGFR） antibody，in patients with locally advanced or metastatic pancreatic cancer.Invest New Drugs，2012，30（3）：1138-1143.

38.Ling Y，chen J，Tao M，et al. A pilot study of nimotuzumab combined with cisplatin and 5-FU in patients with advanced esophageal squamous cell carcinoma. J Thorac Dis，2012，4（1）：58-62.

39.郭兵.帕尼单抗联合化疗治疗晚期头颈部肿瘤的研究.临床和实验医学杂志，2013，12（22）：1811-1814.

40.吕海通.联合帕尼单抗新辅助化疗可手术三阴性乳腺癌患者的疗效.循证医学，2014，14（4）：194.

41.Thatcher N，Hirsch FR，Luft AV，et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage Ⅳ squamous non-small-cell lung cancer（SQUIRE）：an open-label，randomised，controlled phase 3 trial. Lancet Oncol，2015，16（7）：763-774.

42.Herbst RS，Redman MW，Kim ES，et al.A randomized，phase Ⅲ study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer（NSCLC）：SWOG S0819.Presented at：16th World Conference on Lung Cancer.Abstract 3612.